| Previous Close | 177.56 |
| Volume | 4,246,940 |
| Price / Earnings (Forward) | 19.49 |
| Price / Sales | 3.82 |
| Price / Book | 4.04 |
| 52 Weeks Range | |
| TTM Dividend Yield | 2.44% |
| Profit Margin | 18.04% |
| Operating Margin (TTM) | 32.68% |
| Diluted EPS (TTM) | 8.34 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Quarterly Earnings Growth (YOY) | 5.60% |
| Total Debt/Equity (MRQ) | 58.23% |
| Current Ratio (MRQ) | 1.86 |
| Operating Cash Flow (TTM) | 2.95 B |
| Levered Free Cash Flow (TTM) | 1.78 B |
| Return on Assets (TTM) | 6.69% |
| Return on Equity (TTM) | 14.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | CSL FPO [CSL] | - | - |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | -0.06 |
|
CSL is one of the largest global biotech companies and has three main segments. CSL Behring uses either plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D record, and its product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and one-fourth in Europe. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Core |
| % Held by Insiders | 0.30% |
| % Held by Institutions | 35.79% |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |